Teladoc Health, Inc. (NYSE:TDOC) Position Reduced by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. reduced its position in shares of Teladoc Health, Inc. (NYSE:TDOC) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 140,368 shares of the health services provider’s stock after selling 3,751 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A. owned about 0.08% of Teladoc Health worth $1,298,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in Teladoc Health by 13.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 138,687 shares of the health services provider’s stock valued at $1,261,000 after purchasing an additional 15,953 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Teladoc Health by 72.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 36,514 shares of the health services provider’s stock valued at $332,000 after buying an additional 15,364 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Teladoc Health by 3.2% during the 4th quarter. MetLife Investment Management LLC now owns 101,612 shares of the health services provider’s stock valued at $924,000 after acquiring an additional 3,108 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Teladoc Health by 0.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,531,492 shares of the health services provider’s stock worth $32,104,000 after acquiring an additional 8,890 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Teladoc Health by 0.5% during the 4th quarter. Canada Pension Plan Investment Board now owns 228,700 shares of the health services provider’s stock worth $2,079,000 after acquiring an additional 1,200 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Adam C. Vandervoort sold 11,011 shares of Teladoc Health stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $8.42, for a total value of $92,712.62. Following the transaction, the insider now owns 64,308 shares of the company’s stock, valued at $541,473.36. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.58% of the company’s stock.

Teladoc Health Trading Down 1.0 %

NYSE:TDOC opened at $7.19 on Monday. The company has a market capitalization of $1.26 billion, a P/E ratio of -1.25 and a beta of 1.73. The stock’s 50 day moving average price is $8.52 and its 200 day moving average price is $9.57. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. Teladoc Health, Inc. has a 52 week low of $6.35 and a 52 week high of $15.21.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.07). Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The business had revenue of $640.49 million for the quarter, compared to analyst estimates of $639.44 million. On average, research analysts forecast that Teladoc Health, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TDOC. Bank of America reduced their target price on Teladoc Health from $9.50 to $8.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research note on Thursday, February 27th. The Goldman Sachs Group dropped their target price on shares of Teladoc Health from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Oppenheimer reduced their price target on shares of Teladoc Health from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, January 24th. Finally, Piper Sandler decreased their price objective on shares of Teladoc Health from $13.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. Twelve analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.71.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.